Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2018; 10(7): 172-183
Published online Jul 15, 2018. doi: 10.4251/wjgo.v10.i7.172
Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients’ decision making?
Stavros Gkolfinopoulos, Demetris Papamichael, Konstantinos Papadimitriou, Panos Papanastasopoulos, Vassilios Vassiliou, Panteleimon Kountourakis
Stavros Gkolfinopoulos, Demetris Papamichael, Panos Papanastasopoulos, Panteleimon Kountourakis, Department of Medical Oncology, BOC Oncology Center, Nicosia 2006, Cyprus
Konstantinos Papadimitriou, Department of Medical Oncology, University Hospital of Antwerp, Antwerp 2650, Belgium
Vassilios Vassiliou, Department of Radiation Oncology, BOC Oncology Center, Nicosia 2006, Cyprus
Author contributions: Gkolfinopoulos S and Papamichael D participated in manuscript preparation and revision, approval of the final version; Papadimitriou K and Papanastasopoulos P participated in manuscript preparation, approval of the final version; Vassiliou V participated in manuscript preparation; Kountourakis P participated in conception and design of the review, manuscript preparation and revision, approval of the final version.
Conflict-of-interest statement: Dr. Kountourakis has nothing to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Panteleimon Kountourakis, MD, PhD, Attending Doctor, Consultant, Department of Medical Oncology, BOC Oncology Center, 32 Acropoleos Ave, Nicosia 2006, Cyprus.
Telephone: +357-22-847402 Fax: +357-22-841388
Received: March 28, 2018
Peer-review started: March 28, 2018
First decision: April 18, 2018
Revised: May 16, 2018
Accepted: June 13, 2018
Article in press: June 14, 2018
Published online: July 15, 2018
Processing time: 109 Days and 18.9 Hours
Core Tip

Core tip: Despite recent advances in cancer therapeutics, the survival of gastric cancer patients with metastatic disease is dismal due to the complexity of the disease, the constant evolution of tumors and our still limited understanding of its biology. It is evident that a wide spectrum of prognostic and predictive biomarkers is needed in order to rationalize our decisions when managing patients with this specific tumor type and tailor our treatment to suit better the individual patient’s unique needs.